GeoVax Labs, Inc. (NASDAQ:GOVX) Receives $14.20 Average PT from Brokerages

Shares of GeoVax Labs, Inc. (NASDAQ:GOVX) have been given an average rating of “Buy” by the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $14.20.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $18.00 price objective on shares of GeoVax Labs in a research note on Thursday, February 27th.

Institutional Investors Weigh In On GeoVax Labs

Hedge funds have recently modified their holdings of the stock. Northern Trust Corp acquired a new stake in GeoVax Labs during the 4th quarter worth about $29,000. Virtu Financial LLC acquired a new stake in shares of GeoVax Labs during the third quarter valued at approximately $97,000. Citadel Advisors LLC purchased a new stake in shares of GeoVax Labs in the 4th quarter valued at approximately $104,000. Finally, Geode Capital Management LLC boosted its stake in GeoVax Labs by 59.0% in the 4th quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the period. 6.09% of the stock is owned by hedge funds and other institutional investors.

GeoVax Labs Stock Down 5.3 %

NASDAQ:GOVX opened at $1.42 on Friday. The business’s 50-day moving average price is $1.80 and its 200 day moving average price is $2.27. GeoVax Labs has a 52-week low of $1.09 and a 52-week high of $11.18.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.